425: Waters Reports Strong Q2, Raises 2025 Outlook

Waters Corporation reported strong second-quarter 2025 financial results, exceeding guidance and raising full-year outlook, while detailing strategic benefits and integration plans for its pending acquisition of BD's Biosciences and Diagnostic Solutions business.

Summary

• Q2 2025 sales grew 9% reported and 8% in constant currency, exceeding guidance.
• Non-GAAP earnings per share were $2.95, up 12% year-on-year and above the midpoint of guidance; GAAP EPS was $2.47.
• Instruments grew mid-single-digits, led by high-single-digit growth in the LC and mass spec portfolio.
• Recurring revenue grew 11%, driven by 9% service growth and double-digit chemistry growth.
• Pharma segment grew low-double-digits, industrial grew 6%, and academic and government declined low-single-digits.
• Chemistry sales benefited from approximately $8 million pulled forward in Q2 due to tariff dynamics; excluding this, overall constant currency growth was 7% with chemistry up 10%.
• Full year 2025 constant currency sales growth guidance was raised to 5.5% to 7.5%.
• Full year 2025 non-GAAP EPS guidance was raised to $12.95 to $13.05, representing approximately 9% to 10% growth.
• Q3 2025 constant currency sales growth is expected to be 5% to 7%, with adjusted EPS anticipated between $3.15 and $3.25 (8% to 11% growth).
• The proposed combination with BD's Biosciences and Diagnostic Solutions business is expected to create a combined company with 7% top-line and mid-teens adjusted EPS annualized CAGR growth.
• Anticipated $345 million in adjusted EBITDA synergies by year five, including $200 million in cost synergies by year three and $290 million in revenue synergies by year five.

Sentiment

Score: 9

Explanation: The filing presents very strong financial results for the quarter, exceeding guidance and leading to an upward revision of full-year forecasts. The strategic rationale and detailed synergy plans for the significant acquisition of BD's Biosciences and Diagnostic Solutions business are articulated with high confidence, addressing potential concerns and highlighting substantial growth and margin expansion opportunities. The company's core business momentum is robust, and management's track record in integration and operational excellence further bolsters the positive outlook. While some market segments remain soft, the overall picture is one of strong performance and strategic growth.

Positives

• Strong Q2 2025 financial performance with sales and non-GAAP EPS exceeding guidance.
• Raised full-year 2025 constant currency sales growth guidance to 5.5% to 7.5% and non-GAAP EPS guidance to $12.95 to $13.05.
• Robust momentum in core business, with orders outpacing sales.
• LC and mass spec portfolio showed high-single-digit growth, driven by strong instrument replacement and new product adoption.
• Alliance IAS sales grew 300% year-over-year, and Xevo TQ Absolute platforms grew 40%, with Q2 orders for Xevo TQ Absolute XR more than double expectations.
• Maxpeak Premier Columns grew north of 30% in Q2.
• Idiosyncratic growth drivers significantly outpaced targets: GLP testing revenue grew 70% year-over-year, PFAS testing revenue grew over 50% year-over-year, and India revenues grew in the high teens in H1 2025.
• Delivered 200 basis points of price contribution in Q2 and H1 2025.
• Service plan attachment rose 200 basis points to 52% in H1 2025, exceeding the full-year objective.
• eCommerce adoption comfortably above 40% of chemistry revenue.
• Increased CDMO penetration to 27% of pharma revenue.
• BD Biosciences and Diagnostic Solutions business expected to return to positive growth in H2 2025, reaching 4.5% growth in 2026 and 5% in 2027, before returning to historical mid-single-digit plus growth in 2028 and beyond.
• BD's BACTEC supply constraints alleviated and U.S. export licenses for flow cytometry to China reinstated.
• New FACSDiscover S8 flow cytometer orders running well ahead of target just two months post-launch.
• Significant synergy potential from BD acquisition: $345 million in adjusted EBITDA synergies by year five ($200 million cost by year three, $290 million revenue by year five).
• Identified additional growth vectors not included in synergy assumptions: $500 million TAM for mass spec in microbial identification and $300 million market for microbiology in pharma QA/QC sterility testing.
• Strong leadership team with experience in large integrations, with Chris Ross appointed to lead the integration office.

Negatives

• Weakness in the TA division in macrosensitive polymer and materials testing applications, particularly in the Americas and Europe, leading to a 6% decline for TA overall and roughly 20% decline in the US.
• Gross margin for Q2 was 58.3% and adjusted operating margin was 29.1%, reflecting impact of regional sales mix and margin dilution from tariff surcharges.
• Operating tax rate came in at 17.9% due to jurisdictional mix and discrete items, creating a 5 cent headwind to adjusted EPS in Q2.
• Pharma drug discovery and US academic and government funding remain slow, impacting BD's Biosciences business (low teens percentage of BD revenue).
• BD's microbiology business revenue growth rate trailed competition by 180 basis points on a CAGR basis between 2019 and 2024.
• Branded generics LC replacement in China has not yet kicked in.

Risks

• Actual events or results may differ materially from forward-looking statements due to risks and uncertainties outside Waters' control.
• One or more closing conditions for the BD transaction, including regulatory approvals, may not be satisfied or waived on a timely basis or at all.
• Governmental entities may prohibit, delay, or refuse approval for the transaction, or require conditions, limitations, or restrictions.
• Required approval by Waters' stockholders may not be obtained.
• The proposed transaction may not be completed on expected terms, timeframe, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty of the expected financial performance of the combined company.
• Failure to realize anticipated benefits of the proposed transaction, including delays in completion or integration.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• Occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations may affect timing or result in significant costs.
• Evolving legal, regulatory, and tax regimes.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs.
• Actions by third parties, including government agencies.
• Risk that the anticipated tax treatment of the proposed transaction is not obtained.
• Risk of greater than expected difficulty in separating SpinCo from BD's other businesses.
• Disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Other effects of the pendency of the proposed transaction on relationships with employees, customers, suppliers, or other counterparties.

Future Outlook

Waters Corporation has raised its full-year 2025 constant currency sales growth guidance to 5.5% to 7.5% and non-GAAP EPS guidance to $12.95 to $13.05, reflecting robust momentum in its core business. The pending combination with BD's Biosciences and Diagnostic Solutions business is expected to accelerate entry into high-growth adjacencies and drive a combined company financial trajectory of 7% top-line and mid-teens adjusted EPS annualized CAGR growth between 2025 and 2030, supported by $345 million in adjusted EBITDA synergies by year five. The BD business is projected to gradually return to positive growth in the second half of calendar year 2025, reaching 4.5% growth in 2026 and 5% in 2027, before returning to historical mid-single-digit plus growth in 2028 and beyond, with additional upside from anticipated new product launches in 2026.

Management Comments

• "We're pleased to report another strong quarter with sales, again, above the high end of our guidance. This performance reflects strong execution, revitalized innovation, and our successful expansion into higher growth areas, three strategic pillars we set in motion five years ago and continue to deliver with strength and resilience."
• "The momentum in our core business remains strong. This trend provides the foundation for the next phase of growth as we combine with BDs Biosciences and Diagnostic Solutions business. Consistent with our strategy, the transaction accelerates our entry into multiple high growth adjacencies."
• "The combined company anchored by leading brands generating 80% of the revenue and a 70% annual recurring base create a powerful engine for consistent growth and will drive resilience across future CapEx cycles. Paired with highly attained cost and revenue synergies, this positions the company for an impressive financial trajectory with 7% top line and mid-teens adjusted EPS annualized CAGR growth on a combined company basis."
• "We estimate that the underlying BD Bioscience & Diagnostic Solutions business will gradually return to growth through the rest of calendar year 2025. We expect a slight decline in the quarter ending June 30th, with further sequential growth rate improvement and a return to positive growth in the second half of the calendar year, all of which is reflected in our model."
• "We expect to deliver 345 million in adjusted EBITDA synergies by year five, driven by 200 million in cost by year three and 290 million in revenue synergies by year five. The structure and execution plan behind these numbers gives us confidence in how actionable and achievable they are."
• "The BD business we are acquiring closely resembles where Waters stood in 2020, 30% of the installed base is due for replacement. 70% of revenue comes from reagents, yet only a limited percentage flows through eCommerce and only 40% of the installed base is covered under a service plan. These are all levers we pulled at Waters with dramatic impact."
• "The quality of the assets we are bringing from BD into Waters are exceptional, especially in flow cytometry and microbiology. BD is a pioneer flow cytometry and has consistently driven innovation and enabled critical advances across oncology, rare disease, and immune health."
• "What is less apparent at first glance though is the incredible strategic fit of the microbiology business, which is equally as compelling and holds significant value creation opportunity."
• "We faced a similar situation at Waters five years ago. Through focused and disciplined execution we have since delivered outperformance versus the industry. Now, based on our extensive diligence, we are confident we can repeat the success here."
• "The microbiology business has a highly actionable 700 basis points gross margin expansion opportunity. This presents clear potential to add further value creation by applying Waters operational rigor and is not included in our underwriting model."
• "Over the last five years, we have assembled a leadership team with deep experience in transformation and large integrations. I am pleased to announce that Chris Ross, currently senior vice president of global operations at Waters will lead the integration office of our combination with BDs bioscience and diagnostic solutions business."

Industry Context

The filing highlights a mixed industry landscape. While pharma drug discovery and US academic/government funding remain soft, the broader pharma segment, particularly large pharma and CDMOs, shows strong instrument replacement activity and new product adoption. Industrial segments are seeing growth, especially in food and environmental testing, with significant demand for PFAS testing applications. China's industrial segment is benefiting from battery testing, and its academic and government segment from localization and modest stimulus. The pending acquisition of BD's Biosciences and Diagnostic Solutions business positions Waters to capitalize on high-growth adjacencies like bioanalytical characterization, bioseparations, and mass spec in diagnostics, aligning with trends in large molecule QA/QC testing, cell therapy manufacturing, and biomarker identification. The microbiology business benefits from consistent growth trends tied to infectious disease testing, antimicrobial resistance monitoring, and increasing demand for lab automation.

Comparison to Industry Standards

• Waters' core business has demonstrated outperformance versus the industry over the past five years through focused and disciplined execution, a success model intended to be replicated with the acquired BD business.
• The BD microbiology business's revenue growth rate has trailed competition by 180 basis points on a CAGR basis between 2019 and 2024, presenting an opportunity for Waters to apply its operational rigor and commercial execution playbook.
• BD's microbiology business has a 700 basis points gross margin expansion opportunity compared to key competitors, which Waters plans to accelerate.
• Waters' prior integration of EMD Millipore and Sigma Aldrich delivered synergies equal to approximately 8% of the total cost base, providing a benchmark for the current BD acquisition where the outlined $200 million in cost synergies represents just under 5% of the combined company's cost base, suggesting potential for further upside.
• Waters successfully executed a 5% headcount reduction in one quarter in 2023 when demand softened, demonstrating discipline in aligning cost base without compromising performance, a discipline that underpins the current synergy plan.
• Direct procurement savings target of 2.5% of direct material spend is conservative compared to a market benchmark of 5%.
• Indirect procurement savings target of 20 million (less than 2% of combined indirect spend) is also conservative, with meaningful potential upside through rebalancing roles to more cost-efficient hubs.
• Waters' experience with eCommerce adoption, where an incremental dollar is generated for every $5 shifted to digital, will be applied to BD's $1.8 billion reagents business, aiming for a 20% increase in eCommerce attachment to unlock an estimated $75 million in additional revenue.
• The Xevo TQ Absolute XR instrument's robustness, demonstrated by a customer completing over 30,000 uninterrupted plasma injections (up from 3,000), allowed Waters to displace a competitor in a pharma DMPK laboratory.

Management Changes

Stakeholder Impact

• Shareholders: Potential for significant value creation through strong financial performance, raised guidance, and the strategic acquisition of BD's business, which is projected to drive substantial revenue and EPS growth through synergies and market expansion.
• Employees: Integration of BD's business will involve combining teams and potentially rebalancing roles across geographies, offering long-term scalability and flexibility. Chris Ross's appointment to lead integration suggests a structured approach.
• Customers: Enhanced product portfolio and capabilities through new product launches (e.g., Xevo TQ Absolute XR, BioResolve Protein A Affinity Columns) and the integration of BD's technologies (flow cytometry, microbiology). Improved service coverage and e-commerce adoption are also positive for customers.
• Suppliers: Potential impact from direct and indirect procurement savings initiatives as part of synergy realization.
• Creditors: Plans to use free cash flow to pay down $100 million of debt in the second half of the year, improving the net debt position.

Next Steps

• Continue strong commercial execution across the organization.
• Further advance eCommerce adoption and CDMO penetration.
• Leverage new product launches (e.g., BioResolve Protein A Affinity Columns, light scattering on Empower).
• Integrate BD's Biosciences and Diagnostic Solutions business, led by Chris Ross.
• Apply Waters' operational rigor and commercial execution playbook to the acquired BD business, particularly microbiology.
• Realize cost synergies from manufacturing and supply chain, commercial infrastructure, and indirect procurement.
• Realize revenue synergies from commercial excellence, high-growth adjacencies (bioanalytical characterization, bioseparations, mass spec in diagnostics), and cross-selling.
• Support the launch of BD's new products in 2026, including flow cytometry portfolio and next generation BACTEC.
• Explore new growth vectors in mass spec for microbial identification and microbiology for pharma QA/QC sterility testing.
• Pay down $100 million of debt and add to cash position in the second half of the year.

Key Dates

Recommendation

Waters Corporation delivered exceptional Q2 2025 results, surpassing expectations and prompting a significant upward revision of its full-year guidance for both sales and non-GAAP EPS. This demonstrates robust underlying business momentum, effective commercial execution, and successful innovation. The detailed strategic rationale for the acquisition of BD's Biosciences and Diagnostic Solutions business is highly compelling, outlining substantial and actionable cost and revenue synergies ($345 million adjusted EBITDA by year five). The acquisition is expected to accelerate Waters' entry into high-growth adjacencies and drive a combined company revenue CAGR of 7% and mid-teens adjusted EPS CAGR through 2030. Management's proven track record in large-scale integrations and operational improvements, as evidenced by past performance and the appointment of an experienced integration leader, instills high confidence in the successful realization of these benefits. Despite some minor headwinds in specific market segments, the overall outlook is overwhelmingly positive, indicating strong potential for sustained growth and shareholder value creation.

Keywords

Waters Corporation, SEC Filing, Financial Results, Q2 2025 Earnings, Becton Dickinson, BD Biosciences, Diagnostic Solutions, Acquisition, Merger, Synergies, LC-MS, Mass Spectrometry, Chromatography, Pharma, Biotech, Drug Discovery, PFAS Testing, GLP Testing, Microbiology, Flow Cytometry, Lab Automation, Analytical Instruments, Life Science Tools, Corporate Governance, Risk Management, Guidance Update, Investor Relations